G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment? / Ripa, Rasmus Sejersten; Kastrup, Jens.

I: Experimental Hematology, Bind 36, Nr. 6, 06.2008, s. 681-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ripa, RS & Kastrup, J 2008, 'G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?', Experimental Hematology, bind 36, nr. 6, s. 681-6. https://doi.org/10.1016/j.exphem.2008.01.010

APA

Ripa, R. S., & Kastrup, J. (2008). G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment? Experimental Hematology, 36(6), 681-6. https://doi.org/10.1016/j.exphem.2008.01.010

Vancouver

Ripa RS, Kastrup J. G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment? Experimental Hematology. 2008 jun.;36(6):681-6. https://doi.org/10.1016/j.exphem.2008.01.010

Author

Ripa, Rasmus Sejersten ; Kastrup, Jens. / G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?. I: Experimental Hematology. 2008 ; Bind 36, Nr. 6. s. 681-6.

Bibtex

@article{4f3bf511543a4598a515920eaacddade,
title = "G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?",
abstract = "This review of adjunctive therapy with subcutaneous granulocyte-colony stimulating factor (G-CSF) to patients with acute myocardial infarction (AMI) focus on the cardioprotective effects and potential mechanisms of G-CSF and discuss the therapeutic potential of G-CSF. All clinical trials published in peer-reviewed journals identified through PubMed are discussed. G-CSF treatment seems to be safe, and initial unblinded trials in patients with AMI were encouraging. However, larger double-blind placebo-controlled trials have not been able to demonstrate improved myocardial recovery after G-CSF treatment. Current controversies in interpretation of the results include 1) importance of direct cardiac effect of G-CSF vs indirect through bone marrow stem and progenitor cell mobilization, 2) importance of timing of G-CSF therapy, 3) importance of G-CSF dose, and 4) importance of cell types mobilized from the bone-marrow. Cell-based therapies to improve cardiac function remain promising and further experimental and clinical studies are warranted to determine the future role of G-CSF.",
keywords = "Animals, Bone Marrow Transplantation, Cardiotonic Agents, Clinical Trials as Topic, Disease Models, Animal, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Humans, Myocardial Infarction, Treatment Outcome",
author = "Ripa, {Rasmus Sejersten} and Jens Kastrup",
year = "2008",
month = jun,
doi = "10.1016/j.exphem.2008.01.010",
language = "English",
volume = "36",
pages = "681--6",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarction--a relevant treatment?

AU - Ripa, Rasmus Sejersten

AU - Kastrup, Jens

PY - 2008/6

Y1 - 2008/6

N2 - This review of adjunctive therapy with subcutaneous granulocyte-colony stimulating factor (G-CSF) to patients with acute myocardial infarction (AMI) focus on the cardioprotective effects and potential mechanisms of G-CSF and discuss the therapeutic potential of G-CSF. All clinical trials published in peer-reviewed journals identified through PubMed are discussed. G-CSF treatment seems to be safe, and initial unblinded trials in patients with AMI were encouraging. However, larger double-blind placebo-controlled trials have not been able to demonstrate improved myocardial recovery after G-CSF treatment. Current controversies in interpretation of the results include 1) importance of direct cardiac effect of G-CSF vs indirect through bone marrow stem and progenitor cell mobilization, 2) importance of timing of G-CSF therapy, 3) importance of G-CSF dose, and 4) importance of cell types mobilized from the bone-marrow. Cell-based therapies to improve cardiac function remain promising and further experimental and clinical studies are warranted to determine the future role of G-CSF.

AB - This review of adjunctive therapy with subcutaneous granulocyte-colony stimulating factor (G-CSF) to patients with acute myocardial infarction (AMI) focus on the cardioprotective effects and potential mechanisms of G-CSF and discuss the therapeutic potential of G-CSF. All clinical trials published in peer-reviewed journals identified through PubMed are discussed. G-CSF treatment seems to be safe, and initial unblinded trials in patients with AMI were encouraging. However, larger double-blind placebo-controlled trials have not been able to demonstrate improved myocardial recovery after G-CSF treatment. Current controversies in interpretation of the results include 1) importance of direct cardiac effect of G-CSF vs indirect through bone marrow stem and progenitor cell mobilization, 2) importance of timing of G-CSF therapy, 3) importance of G-CSF dose, and 4) importance of cell types mobilized from the bone-marrow. Cell-based therapies to improve cardiac function remain promising and further experimental and clinical studies are warranted to determine the future role of G-CSF.

KW - Animals

KW - Bone Marrow Transplantation

KW - Cardiotonic Agents

KW - Clinical Trials as Topic

KW - Disease Models, Animal

KW - Granulocyte Colony-Stimulating Factor

KW - Hematopoietic Stem Cell Mobilization

KW - Humans

KW - Myocardial Infarction

KW - Treatment Outcome

U2 - 10.1016/j.exphem.2008.01.010

DO - 10.1016/j.exphem.2008.01.010

M3 - Journal article

C2 - 18358590

VL - 36

SP - 681

EP - 686

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 6

ER -

ID: 47743910